Phase 4 N=92 Acute Psychotherapy for Bipolar II Depression
Bipolar Disorder · Depression
Primary: Remission — 16; 13 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=86 Maintenance Treatment of Bipolar Depression
Bipolar Disorder · Depression
Primary: Mania Rating Scale — 4.54; 5.57 units on a scale
Phase 3 N=119 Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Bipolar Disorder · Bipolar Depression
Primary: MADRS Rating Scale Change — 13.1; 15.2 units on a scale — p=0.17
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
Phase 2 N=50 Scopolamine in Bipolar Depression
Bipolar Disorder Depression
Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3
Phase 3 N=57 Lamotrigine for Symptoms of Geriatric Bipolar Depression
Bipolar Disorder · Depression, Bipolar
Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
N/A N=35 Levetiracetam in the Management of Bipolar Depression
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale (HDRS-21) Total Score From Baseline at Week 6. — -2.7647; -4; -3.4259; -6.5875 score on scale — p=0.29
Phase 3 N=525 A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
Phase 4 N=7 Tranylcypromine Treatment of Bipolar Depression
Bipolar Disorder I or II
Primary: 29 Item Hamilton Rating Scale for Depression (HamD29) — 27.0; 5.8 Hamilton Depression score
N/A N=10 iTBS in Bipolar I Depression
Bipolar Depression · Bipolar I Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score — 16.9 score on a scale
Phase 4 N=177 Prevention of Relapse & Recurrence of Bipolar Depression
Bipolar Disorder
Primary: Number of Participants With Relapse of Major Depressive Episode Within 1 Year — 4; 5 Participants
N/A N=7 Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression
Treatment Resistant Depression
Primary: Change From Baseline Montgomery Asberg Depression Rating Scale (MADRS) — 40.0; 5.7 score on a scale
N/A N=26 Intensive TMS for Bipolar Depression
Bipolar Depression · Treatment Resistant Depression
Primary: Clinical Efficacy of High Dose Spaced Theta Burst (HDS-TBS) — 30.4; 28; 10.5; 25.3 score on a scale — p=<0.001
Phase 4 N=65 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Bipolar Depression
Primary: Response to Treatment — 21; 9; 6; 11 Participants — p=.02
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044
Phase 3 N=505 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
Bipolar Depression
Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -10.7; -15.4; -15.4 units on a scale — p=<0.001
Phase 3 N=554 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.9; -20.7; -19.7 score on a scale — p=0.514
Phase 3 N=62 Bipolar Depression Before and After Lamotrigine Treatment
Bipolar Depression
Primary: Mean Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline for Both Groups, and After 12 Weeks of Lamotrigine Monotherapy for the Bipolar Group — 27.79…
Phase 2 N=116 A Study of JNJ-55308942 in the Treatment of Bipolar Depression
Bipolar Disorder
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6 — -16.0; -15.4 Units on a scale — p==0.438
Phase 2 N=22 Sequential Therapy for the Treatment of Severe Bipolar Depression.
Bipolar Depression · Suicidal Ideas · Suicidal Ideation
Primary: BDM Score (BISS-derived MADRS) Change From Baseline at Day 42 — 3.3; 2.4; -1.06; 0 score on a scale — p=.03
Phase 4 N=32 12- Week Open Label Treatment of Refractory Bipolar Depression
Bipolar Disorder
Primary: Primary Measure:Reduction in Depression Symptoms — 16 participants
Phase 3 N=514 Olanzapine Treatment of Patients With Bipolar I Disorder
Depression, Bipolar
Primary: Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) — 29.36; 28.69; -14.26; -11.71 units on a scale — p=0.018
Phase 2 N=38 N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
Bipolar Disorder
Primary: Number of Patients Demonstrating a > 50% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) — 3; 2; 5; 6 Participants
N/A N=14 Riluzole in the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale — -12.6 units on a scale — p=<.001
Phase 3 N=298 Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
Bipolar Disorder · Depression, Bipolar
Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.7; -13.2 scores on scale — p=0.7921
Phase 4 N=41 Iloperidone in Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale…
N/A N=69 Lamotrigine Therapy in Geriatric Bipolar Depression
Bipolar Depression
Primary: Mean Glutamine to Creatine Ratio by Diagnosis at Baseline — .34; .36 mean serum Glutamine to Creatine ratio
Phase 4 N=34 Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
Metabolic Syndrome · Bipolar Depression · Insulin Resistance
Primary: Change in the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Score — -16.5 units on a scale